UBS analyst Ashwani Verma raised the firm’s price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes Arcellx’s anito-cel has generated similar efficacy and better safety profile compared to Legend Biotech’s (LEGN) Carvykti, and while Legend bulls may argue Arcellx “cherry-picked” patients, the firm believes that the data speaks for itself and settles the debate, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Gilead price target raised to $115 from $105 at Oppenheimer
- Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole
- Arcellx price target raised to $115 from $73 at Barclays
- Arcellx, Inc. Reports Q3 2024 Earnings Highlights
- Arcellx price target raised to $136 from $87 at Truist